ClinicalTrials.gg
RecruitingNCT07056699Updated Jul 20, 2026

SGLT2i, Pioglitazone, and Ketone Production in T1D

A Phase 3 interventional study of Dapagliflozin 10mg Tab and Pioglitazone 15 MG and 30mg in Type1diabetes, sponsored by The University of Texas Health Science Center at San Antonio. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-20.

Sponsored by The University of Texas Health Science Center at San Antonio · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jul 2026; still recruiting 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 1,458 studies in Diabetes Mellitus, Type 1 with a site in United States — 190 open to participants now, 257 under way, 17 of them phase 3. Diabetes Mellitus, Type 1 · United States.

Planned enrollment
801st of 1,242
24 · median 40
Started
2026
with 61 others
Phase 3
147 of 1,458
10 open now
Primary completion
2027-06
later than 130 of 256 live
Registered
1,377th of 1,458
by date

Among the 1,458 studies in Diabetes Mellitus, Type 1 with a site in United States, this one is the 801st largest by planned enrollment of the 1,242 interventional ones that give a count, is one of 62 that started in 2026, is one of 147 in phase 3, reaches primary completion later than 130 of the 256 other live ones, and was the 1,377th registered.

Diabetes Mellitus, Type 1

3,758 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.

Browse Diabetes Mellitus, Type 1 studies →

Open to participants now

190 of the 1,458 studies in Diabetes Mellitus, Type 1 with a site in United States are open now. Recruiting first, the newest first:

185 more — sign in →

All 190 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 417 Diabetes Mellitus, Type 1 studies recruiting now, 130 (31%) set no upper age limit and 261 (63%) stop at 75 or younger; 187 take children under 18; 66 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,458 studies in Diabetes Mellitus, Type 1 with a site in United States, or all of them as a file.
02

Study summary

Participants are being asked to be in a research study. Scientists do research to answer important questions which might help change or improve treatment of participants disease in the future.

In patients with Type 1 Diabetes (T1D), dapagliflozin a Selective Glucose Transporter 2 Inhibitor (SGLT2i) is known to increase production of glucose in the liver, increase breakdown of fats (lipolysis), and increase production of ketones (ketogenesis). Ketones are chemicals produced by the liver when the body breaks down fat for energy instead of glucose. When the level of ketones in the body becomes too high, a condition called ketoacidosis develops. In this study, the study team will investigate whether adding pioglitazone (a medication commonly used to treat type 2 diabetes), can reduce the dapagliflozin - induced liver glucose production, fat break down (lipolysis) and ketone body production (ketogenesis) in patients with T1D.

Read the detailed description

The purpose of this research study is to investigate the effects of dapagliflozin and pioglitazone in the body - specifically, on liver glucose production, breakdown of fat, and ketone production in T1D patients treated with insulin. Subjects with T1D can't make insulin because their pancreas doesn't work properly. This means they need insulin injections to control their blood sugar. But using insulin can sometimes cause low blood sugar and weight gain, making it harder for insulin to work and requiring higher doses. Finding other medicines that can help lower blood sugar in people with T1D and can be used along with insulin would make it easier to manage their blood sugar.

Dapagliflozin is in a class of drugs known as SGLT2i and has been shown to effectively lower blood sugar concentration in T1D patients. These drugs lower blood glucose levels by preventing or reducing the re-absorption of glucose in the kidneys. This results in the release of glucose into the urine. At the same time, SGLT2i drugs stimulate glucose production by the liver, which helps compensate for the loss of glucose into the urine. Also, the use of dapagliflozin in patients with type 1 diabetes was associated with increased risk of ketoacidosis. Ketoacidosis is a serious condition that occurs when the body produces high levels of ketones, leading to increased acidity in the blood. Pioglitazone is in a class of thiazolidinediones and is commonly used to treat high blood sugar levels caused by type 2 diabetes. The investigators believe that the addition of pioglitazone, to dapagliflozin will prevent the risk of ketoacidosis associated with dapagliflozin, and will cause a large reduction in plasma glucose concentration in T1D patients.

03

Conditions studied

  • Type1diabetes

Keywords

  • Selective Glucose Cotransporter 2 inhibitors (SGLT2i)
  • Dapagliflozin
  • Pioglitazone
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age >18 years
  2. T1D
  3. Other than diabetes, subjects must be in good general health as determined by the investigator based on physical exam, medical history and screening labs.

    Minor deviations may be permitted if:

    • The abnormality is not considered .
    • The deviation does not pose a safety risk or interfere with study participation.
    • The rationale for inclusion is documented in the source records.
  4. Fasting C-peptide concentration \<0.7 ng/ml
  5. Poor glycemic control (=7.0-11.0%)
  6. Treatment with multiple daily insulin injections (basal plus prandial) or insulin pump
  7. Total daily insulin dose ≥0.6 U/kg per day
  8. Stable insulin dose (±4 units) in the preceding three months
  9. ≥ 50 ml/min
  10. Weight stable over the preceding 3 months (± 4 pounds)
  11. Positive GAD antibody (Glutamic Acid Decarboxylase antibody). *

    • Testing for GAD antibodies will be performed during the screening visit. Participants who test positive for GAD antibodies will be eligible for enrollment in the study. Over time, these antibodies may disappear, reducing the likelihood of a positive result during screening. If participant tests negative for GAD antibodies, their medical history will be reviewed to determine whether testing for GAD antibodies was performed at an earlier stage of Type 1 Diabetes (T1D). If prior positive results are confirmed, the participant may be enrolled. If a participant tests positive for antibodies other than GAD, an exception request will be submitted to the Institutional Review Board (IRB) for approval.

Exclusion criteria

EXCLUSION CRITERIA

  1. Type 2 Diabetes (T2D)
  2. Daily insulin dose \<0.6 U/kg per day
  3. Fasting C-peptide >0.7 ng/ml
  4. \<7.0% or >11.0%
  5. \< 50 ml/min
  6. Hematuria in urine analysis
  7. Pregnancy, lactating, positive pregnancy test or planning to become pregnant in the following year. Women of will be required to undergo a pregnancy test prior to enrollment and must agree to use effective (at least two barrier methods) for the duration of the study.
  8. Major organ system disease which includes: (i) or history of malignancy including bladder cancer; (ii) Congestive heart failure or history of coronary heart disease or any other cardiac disease; (iii) chronic liver disease or LFT >3 times the upper normal level; (iv) History of alcohol or drug abuse; (v) History of chronic lung disease (e.g., , asthma); (vi) history of rheumatic disease; (vii) History of chronic pancreatitis or pancreatic surgery; (viii) History of CVA or (ix) Planned surgery during the study; (x) history of infection or other immune compromised disease; and history of organ transplantation; (xi) patients who take medications, other than insulin, known to affect glucose metabolism, e.g., prednisone.
  9. Evidence of proliferative diabetic retinopathy
  10. Patients enrolled in a heavy exercise program
  11. Patients on ketogenic diet
  12. History of hospitalization for DKA, hypoglycemia or uncontrolled hyperglycemia in the preceding 6 month.
  13. Presence of symptoms of poor glycemic control, e.g. polydipsia or polyurea
  14. History of to dapagliflozin or pioglitazone
  15. Participants with a history of radiation exposure exceeding 5 REM within the previous 12 months will be excluded.

Prior to the screening period, potential participants will be pre-screened either by phone or in person at the Texas Diabetes Institute. Individuals with prior significant radiation exposure will be excluded.

Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
24 participants (estimated)

Study arms

  • Experimental
    Experimental study drug for T1D

    Dapagliflozin (10 mg/day) + Pioglitazone (15 mg/day for 2 weeks, then 30 mg/day for 14 weeks)

    Drug: Dapagliflozin 10mg Tab · Drug: Pioglitazone 15 MG and 30mg

  • Placebo comparator
    Placebo Group for T1D

    Dapagliflozin (10 mg/day) + Placebo (for 16 weeks)

    Drug: Dapagliflozin 10mg Tab · Other: Placebo

Interventions

  • DrugDapagliflozinStudies of DapagliflozinDapagliflozin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Dapagliflozin (10 mg/day)

    Also known as: Farxiga

  • DrugPioglitazone 15 MG and 30mg

    Drug page: PioglitazoneStudies of PioglitazonePioglitazone pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Pioglitazone (15 mg/day for 2 weeks, then 30 mg/day for 14 weeks)

    Also known as: Actos

  • OtherPlacebo

    Inert placebo for Pioglitazone

    Also known as: Inert substance

06

What researchers measure

Primary outcomes

  1. Change in endogenous glucose production (EGP)

    Infusions of a tracer, ³H-glucose, will begin and continue until the end of the study. A single dose of empagliflozin (25 mg) by mouth will be taken at 900am. Blood samples will be collected minutes to assess how your body responds to the infused tracers. This tracer help to measure the rate of endogenous (liver) glucose production. The difference in levels of EGP will be reported from the beginning of the study to a second level taken 16 weeks later.

    Time frame: Baseline (Week 0) to Week 16

  2. Change in ketone body production ( ketogenesis)

    Infusions of tracers, ³H-glucose and U-2H-glycerol or 14C-Glycerol, will begin and continue until the end of the study. A single dose of empagliflozin (25 mg) by mouth will be taken at 900am. Blood samples will be collected to assess how your body responds to the infused tracers. This tracer help to measure the rate of ketone body production (ketogenesis). The difference in levels of ketones will be reported from the beginning of the study to a second level taken 16 weeks later.

    Time frame: Baseline (Week 0) to Week 16

  3. Change in lipolysis (fat breakdown)

    Infusions of tracers, U-H-14C-Glycerol or 2H-Glycerol, will begin and continue until the end of the study. A single dose of empagliflozin (25 mg) by mouth will be taken at 900am. Blood samples will be collected to assess how your body responds to the infused tracers. This tracer help to measure the rate of lipolysis (fat breakdown). The difference in levels of lipolysis will be reported from the beginning of the study to a second level taken 16 weeks later.

    Time frame: Baseline (Week 0) to Week 16

Secondary outcomes

  1. Change in HbA1c from baseline (Week 0) to Week 16

    HbA1c and CGM metrics provide clinically relevant data on glycemic control and variability. This endpoint assess the metabolic efficacy of adding pioglitazone to dapagliflozin in T1DM.

    Time frame: Baseline (Week 0) to Week 16

  2. Change in plasma Free Fatty Acid (FFA) from baseline (Week 0) to Week 16.

    Measuring free fatty acids directly tests the hypothesis that pioglitazone reduces the risk of SGLT2 inhibitor-associated diabetic ketoacidosis (DKA) by suppressing FFA release.

    Time frame: Baseline (Week 0) to Week 16

  3. Change in glycerol from baseline (Week 0) to week 16.

    To examine the effects of adding pioglitazone (15/30 mg/day) to dapagliflozin (10 mg/day) compared to dapagliflozin (10mg/day) plus placebo in T1DM patients, focusing on lipolysis changes over a 16-week treatment period.

    Time frame: Baseline (Week 0) to Week 16

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Study participant research data, which is for purposes of statistical analysis and scientific reporting, will be transmitted to and stored at the Diabetes division at UT Health. This will not include the participant's contact or identifying information. Rather, individual participants and their research data will be identified by a unique study identification number. The study data entry and study management systems used by clinical sites and by Diabetes division at UT Health research staff will be secured, and password protected. At the end of the study, all study databases will be de-identified and archived at the Diabetes division at UT Health.

Supporting information: Study protocol, Statistical analysis plan

Time frame: At the end of the study, after data analysis is complete.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2026 (actual). Primary completion is estimated for Jun 2027, 11 months after the start.

Of 108 phase 3 interventional studies under Diabetes Mellitus, Type 1, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 27. This study's planned 11 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 26, 2025
First posted
Jul 9, 2025
StartActual
Jul 1, 2026
Primary completionEst.
Jun 1, 2027
CompletionEst.
Jun 30, 2027
Last update
Jul 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 20, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07056699
Responsible party
Sponsor
First posted
Jul 9, 2025
Start date
Jul 1, 2026
Primary completion
Jun 1, 2027 (estimated)
Completion
Jun 30, 2027 (estimated)
Last update
Jul 20, 2026

Study contacts

Ralph DeFronzo, MD
Contact
defronzo@uthscsa.edu
210 567 6691
Aurora Merovci, MD, MPH
Contact
merovci@uthscsa.edu
210 358 7409
Muhammad Abdul-Ghani, MD
principal investigator · The University of Texas Health Science Center at San Antonio
Ralph DeFronzo, MD
principal investigator · The University of Texas Health Science Center at San Antonio

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pioglitazone

Start the discussion